Page 1 of 7, Inc. (CIIX)

PostPosted: Mon Jan 23, 2017 10:59 am
by QualityStocks
Founded in 1999, has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

Re:, Inc. (CIIX)

PostPosted: Mon Jan 23, 2017 4:53 pm
by QualityStocks, Inc. (CIIX) Covered in New Report from WallStreet Research™

Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering, Inc. (OTCQB: CIIX). In addition to highlighting CIIX’s ongoing operations, including both its efforts to provide a range of financial information to the global Chinese population via and its preparations to capitalize on the thriving market for cannabidiol-based products through its website, the WSR report gives prospective investors some additional insight into the tremendous growth opportunities presented by the company’s evolving strategy.

“The Company’s recent announcements regarding expansion into the medical marijuana and CBD oil industry has driven great interest in CIIX shares,” Alan Stone, managing director of WSR, stated in this morning’s news release. “As a result, the shares have significantly increased in both market value and trading volume, potentially positioning the company for a listing either on the NASDAQ or the NYSE Markets sometime later in 2017.”

In recent weeks, CIIX has made considerable progress toward the impending launch of its operations in the emerging global cannabis industry. Last month, the company announced a new partnership with a well-known cannabidiol (CBD) health brand that will enable CIIX to retail nutritional supplements containing CBD to the Asian market through both online and in-store distribution channels. Shortly after that announcement, CIIX unveiled plans to launch the world’s first CBD health products online store available in the Chinese language by the end of January 2017. The headquarters for this operation will be located in Shanghai, and the company has already outlined plans to create a wholly-owned subsidiary within the Shanghai Free Trade Zone with the sole focus of supplying CBD-based health products to the expansive worldwide Chinese population.

This morning’s release of a research report from WSR came just days after the release of a similar update from Traders News Source (TNS), an equity research firm specializing in small and micro-cap securities. The TNS report also placed a great deal of focus on CIIX’s recent entry into the cannabis industry through The firm notes that, while marijuana use is currently illegal in the People’s Republic of China, cannabis-based oils are legal, providing a potential market for CIIX that includes well over one billion people in China alone.

For more information, visit

Re:, Inc. (CIIX)

PostPosted: Tue Jan 24, 2017 5:17 pm
by QualityStocks
Global Cannabis Growth Spurs, Inc. (CIIX) Cannabidiol Plans in China

The strategy by, Inc. (OTCQB: CIIX) to open the first cannabidiol (CBD) online retail store in China, and to use a wholly-owned subsidiary in the retail and wholesale business to supply CBD health oil products throughout Asia, has attracted the attention of investors who have seen global activity in the cannabis market grow. operates a website for Chinese-speaking investors located in China and the U.S. Its self-directed investing model includes education products and services such as consulting. The company previously announced plans to open a retail store in the Shanghai Free Trade Area and commence distribution of CBD health oil products to Chinese people located around the globe. It expects to go live with its site later this month.

Investment companies have already seen the growth of the cannabis industry globally. Marijuana is not legal in China, but oils that are cannabis-based are. Medical and recreational marijuana is growing globally. Some countries permit medical marijuana only. Legal sales are growing throughout the world and CIIX sees an important opportunity in China and Asia.

Matt Karnes of GreenWave Advisors ( projects that the CBD market in the U.S. could reach almost $3 billion by 2021. Warren Wang, founder and CEO of CIIX, cited the CBD Report in the Hemp Business Journal that the U.S. hemp and legal marijuana consumer sale industries could grow to $2.1 billion by 2020. The ArcView Group sees industry sales throughout North America growing to a little more than $8 billion by the end of 2017.

In a recent news release, Wang added that CIIX has entered into a wholesale agreement with a well-known manufacturer of CBD oil. He anticipates that, through its online platform and retail store, CIIX will be able to retail nutritional supplements containing CBD to China and other Asian markets.

Legalization of marijuana is happening globally. According to TMFUltraLong (, you can use or buy it in some form in Canada, Australia, the Netherlands, France, Uruguay, Chile, Czech Republic, Colombia, and Jamaica. In the U.S., 28 states and the District of Columbia have legalized medical marijuana. To date, a total of 16 states have legalized CBD.

For more information, visit

Re:, Inc. (CIIX)

PostPosted: Wed Jan 25, 2017 4:31 pm
by QualityStocks, Inc. (CIIX) Engages NetworkNewsWire for Corporate Communications Solutions, Inc. (OTCQB: CIIX), the premier financial information website for Chinese-speaking investors in both the U.S. and China, today announced that it has engaged the expertise of NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s solutions help public and private organizations find their voice and build market visibility via social media and a rapidly expanding distribution network of well over 5,000 key syndication outlets.

“ has a strong history of providing investment-based education products and services. We are now taking significant strides to expand our operations and capitalize on the lucrative growth of the cannabis industry with the upcoming and previously announced launch of,” says Warren Wang, founder and CEO of CIIX. “This is an opportunity we certainly do not want to miss, and one that will require enhanced communication and transparency for existing and potential shareholders. At this time of incredible growth, we are pleased to partner with NNW to ensure effective and far-reaching communication to the investment community.”

As part of the Client-Partner relationship between the companies, NNW will leverage its investor-based Brand Network of partners, various newsletters, social media channels, editorial articles, and other outreach tools to generate greater brand awareness for CIIX.

“CIIX has drawn specific blueprints to expand its focus to include the online sale of cannabidiol (CBD)-based nutrition and health products in China, a relatively untapped market with unseen potential,” states Sherri Franklin, director of Content Marketing for NNW. “We are coming alongside CIIX at a time when effective communication is critical to success, reputation and corporate growth. We look forward to helping Warren’s team build a presence in the cannabis industry while maintaining its long-standing position as a financial information website.”

For more information, visit

Re:, Inc. (CIIX)

PostPosted: Mon Jan 30, 2017 5:41 pm
by QualityStocks, Inc. (CIIX) CEO Set to Present at NobleCon13

Premier financial information company, Inc. (OTCQB: CIIX) this morning announced that CEO Warren Wang will be presenting at NobleCon13 on Tuesday, January 31, 2017, at 2:30 PM Eastern Time. The conference, which is currently underway at the Boca Raton Resort & Club in Boca Raton, Florida, is hosted by Noble Capital Markets and focuses on emerging growth companies with less than $2 billion in market capitalization.

For interested investors who are unable to attend NobleCon13, CIIX plans to make a high-definition video webcast of its presentation, as well as a copy of the presentation materials, available on its website at The CIIX presentation will also be available as part of the complete catalog of NobleCon13 presentations at

In recent weeks, has given prospective shareholders plenty of reason for excitement, as the company continues to prepare for its entry into the thriving global cannabidiol (CBD) market. In December, CIIX announced a new wholesale agreement that will enable the company to retail a line of nutritional supplements containing CBD to the Asian market through both online and in-store sales. Shortly after this update, unveiled the new headquarters of its operations in Shanghai, China. Upon launch, the new site is expected to be the world’s first CBD health products online store available in the Chinese language, giving CIIX access to an expansive global market.

“China has a consumer base of nearly 2 billion people and this large population affords an outstanding opportunity to be the provider of choice for CBD oil products to them,” Warren Wang, founder and CEO of CIIX, stated in a recent news release. “CIIX is very excited to be the world’s first listed Chinese company promoting CBD health products that will help Chinese people improve their health status.”

Much like the wider legal cannabis industry, the global market for CBD is expected to experience a period of rapid growth in the coming years. While global statistics are difficult to come by in the face of evolving legislation, the U.S. market could give some insight into international demand. Hemp Business Journal, a market research firm focused on the burgeoning U.S. hemp industry, recently forecast that consumer sales of CBD products in the U.S. could climb to $2.1 billion by 2020, representing an increase of 700 percent from 2016.

For more information, visit

Re:, Inc. (CIIX)

PostPosted: Wed Feb 01, 2017 5:18 pm
by QualityStocks, Inc. (CIIX) Discusses Recent Achievements Driving Aggressive Plans for 2017

On Monday, January 30, 2017, Alan Klitenic, the Director of Investor Relations for, Inc. (OTCQB: CIIX), was interviewed by NetworkNewsWire. Mr. Klitenic described the company, and the growing underserved market it has managed to successfully tap, some of the company’s achievements over the past year, and the aggressive goals it is already pursuing for 2017.

Salient points include the following:

Description –, Inc. is a unique financial media service that is tailored to the ethnic Chinese speaking population in the U.S. and Canada. Founded by long-time financial professional Warren Wang, it’s an American company, but with a strong Chinese orientation, allowing it to connect to the Chinese community with singular effectiveness. Over the years, the company has built its reputation in that community by providing valuable real-time market commentary and analysis on U.S. investor markets, through a range of subscription and other services. In conjunction with this, the company offers investor relations services to small cap and emerging growth organizations, exposing them to the company’s impressive but hard to reach client base in a way nobody else can. CIIX also offers consulting services to companies wishing to enter the public markets.

Achievements, 2016 – The growing significance of the company’s link to the Chinese-speaking community is seen by the increase in quarter-to-quarter revenues for the year. As part of a consistent effort to leverage this most important asset, the company took the initial steps to dovetail its unmatched market connections with one of the fastest growing consumer markets in history, the legal cannabis industry. Realizing that this was a major underserved market for its community, the company signed an agreement with a San Diego producer for the distribution of CBD oil products. These hemp oil derived products are non-toxic, non-addictive, and are legal in all 50 U.S. states, as well as in China, since they are not THC based.

Goals, 2017 – In light of the massive potential of crossing the North American and then worldwide Chinese speaking market with the explosive growth of legal cannabis-based products, the company has just launched its own website, designed to sell CBD oil products not only to its existing client base in North America, but also now to the Chinese mainland, where nobody is yet selling these products. As part of this rapidly developing program, the company is now planning to set up its own operations in China for the production and sale of proprietary CBD oil products. CIIX even plans to develop a CBD oil based pharmaceutical to address the major problem of epilepsy in China, for which the company anticipates formal government approval within the next 2-4 years. The company is also in the final stages of developing its own consumer app that will give Chinese-speaking consumers location-based information relating to available retail outlets.

CIIX founder and CEO Warren Wang is quoted as saying that the overall CBD market is expected to pass $2.1 billion in consumer sales by 2020, so the launch of the company’s new online store, the first of its kind to provide CBD oil products to the Chinese speaking market, is timely.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Thu Feb 02, 2017 4:25 pm
by QualityStocks, Inc. (CIIX) Revenues Rise For Quarter, Six Months Ended November 30, 2016, Inc. (OTCQB: CIIX) filed form 10Q with the SEC on January 23, 2017, stating that it had sharply higher revenues in both the quarter and six months ended November 30, 2016, as compared to the same periods of the prior year. In this filing for its second quarter in fiscal year 2017, it also revised its financials for the year ended May 31, 2016, terming that refiling an immaterial correction.

The company reported revenues of $510,944 for the three months ended November 30, 2016. That marked a 133% jump compared to revenues of $219,263 for the same period of the prior year. For the six months ended November 30, 2016, its revenues were $852,268, a 121% increase compared to $385,592 from the same period of the prior year. In the filing, CIIX attributed the gains to more advertising, additional personnel in the U.S. and China, sophisticated new promotions such as multi-media and roadshows, and greater servicing of a larger base of clients., Inc., a financial consulting company, operates a website for Chinese speaking investors located in China and the U.S. It offers consulting, educational products and other services. Its primary revenue streams had been subscriptions and investor relations. It announced plans to open, in January 2017, a retail store in Shanghai and distribute Cannabidiol (CBD) products online on the site. The site went live in January 2017, giving CIIX an important marketing opportunity in China and Asia.

Marijuana is not legal in China, but oils that are cannabis-based are., Inc., will market health oil products to the Chinese people, it said. The company has attracted significant interest from the financial markets due to these cannabis marketing plans and presented on January 31, 2017, at the NobleCon13 Investor Conference in Florida.

On January 19, 2017, the company filed a Form D Notice to the SEC, disclosing that, through a private placement, it was offering five million shares of its Series C preferred stock at $1 per share. Inc., said funds raised will be used for operating activities and to retire a $660,000 loan, which has a maturity due date of February 28, 2017. As of January 23, 2017, the company said it had raised $4.7 million in cash from various individuals.

In the 10Q, it said it under reported its revenue by $42,500 for the year ended May 31, 2016. On its balance sheet, as of May 31, 2016, total assets were under reported by $171,600, total liabilities were understated by $2,575, and total shareholders’ equity was understated by $169,025. It said it plans to revise its financial statements for some quarterly periods through subsequent filings.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Thu Feb 09, 2017 4:30 pm
by QualityStocks, Inc. (CIIX) Aiming to Help Tackle Epilepsy with a CBD Oil-Based Pharmaceutical, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.

CBD, also known as cannabidiol, is one of the most important healing substances in the hemp plant, helping treat inflammation, convulsions, insomnia, anxiety, ulcers, neuropathic pain, and epilepsy, among other medical problems. The difference between CBD and THC is that THC is classified as a federally controlled psychotropic drug, whereas CBD is recognized as not only safe but legal.

In an article entitled ‘Can Cannabis Oil Treat Seizures?’ by (, results from clinical studies in which doctors treated patients suffering from seizures with CBD showed that Cannabidiol reduced seizures by a monthly average of 36.5%, five patients no longer had motor seizures, and two patients’ seizures completely stopped.

Despite this, the evidence was deemed insufficient as there was not enough to make a solid case, the studies did not include placebo controls, and certain patients stated that they were taking other anti-epilepsy drugs during the clinical trials. However, although these particular trials were not deemed sufficient to prove CBD could potentially treat epileptic seizures, scientists have growing enthusiasm for the use of cannabidiol as a treatment.

There are now several pharmaceutical companies conducting clinical trials of CBD-based drugs, according to The Pharmaceuticals Journal ( These trials will offer guidance on dosage, efficacy, concerns regarding side effects, and the safety of CBD as a form of treatment. With this in mind, recently launched its own website, with the aim of selling CBD oil products to not only clients in the U.S., but also to those on the Chinese mainland.

Although the use of cannabis is not legal in China, CBD is. As a result, the company is acting as a first mover in the market, soon to be offering its own consumer application that will offer Chinese-speaking consumers location-based information about where to buy the products in question. The company plans to acquire formal government approval for its CBD oil-based pharmaceutical to treat epilepsy in the next two to four years.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Feb 15, 2017 5:15 pm
by QualityStocks
SeeThruEquity Report Highlights Recent, Inc. (CIIX) Investments

A SeeThruEquity report released in February revealed that, Inc. (OTCQB: CIIX), a specialized investment services company targeting primarily the Chinese-speaking population in the U.S., has made several investments in the global cannabis industry, increasing its growth potential. Still in the early stages of market penetration, the company cited significant potential in its legal cannabis initiatives. Catalysts for potential future growth include a current stake in Medicine Man Technologies, Inc. (OTCQB: MDCL), a business with cultivation, production, and dispensary operations, which has already generated proceeds from stock sales.

The company’s recent achievements include completing a $5 million private placement of Series C-2016 convertible preferred stock, per a NetworkNewsWire release ( Revenue growth was reported for three consecutive quarters as the company was preparing to expand sales in the United States and China through a new website. Revenues were significantly higher over three- and six-month periods ended November 30, 2016, as operating revenues increased by 133% and 121% over those respective time frames. Long term plans include opening physical retail stores in the United States and elsewhere around the globe.

In January, the company launched its cannabidiol (CBD) health products store online, noted as the first of its kind in the Chinese language. The website sells CBD-containing nutritional supplements and provides a portal for retail destinations to sell products in-store. Extracted from cannabis, CBD oil is non-toxic and non-addictive and is being increasingly accepted for its medicinal properties. Potential has been seen in the treatment of conditions such as anxiety and stress, epilepsy, Alzheimer’s disease, and cirrhosis of the liver. In addition, the company plans to launch a mobile app for locating cannabis dispensaries and discussing related products in the U.S. This follows a December 2016 announcement ( that it had formed an alliance with Shenzhen Yuanrong PE Capital, a private equity firm, to pursue medical/recreational cannabis business opportunities.

SeeThruEquity sees, Inc. as a high-risk/high-reward investment opportunity, with potential for further growth if there is renewed traction with its investor relations services businesses. The company reported revenue had reached $510,944 in the second quarter of fiscal year 2017, an increase from the August quarter revenue of $341,324. Also, it reported $1.4 million in assets and $636,345 in available cash during the first two quarters of fiscal 2017., Inc. was founded in 1999, in Colorado, to serve the U.S. Chinese-speaking population with stock market data and investment information. It is led by CEO Warren Wang, who was born in Shanghai, China, and has over 15 years of experience in the financial markets industry. He has worked in management, sales, project management, marketing, and accounting. Quoqi Deng is the company’s CFO and previously worked with the Shenyang Technological Development Zone for 12 years, introducing billions in overseas capital to fund a major construction project in China. The company aims to inform individual investors so they can make financial decisions and achieve their goals. It uses an investment method that integrates support, web-based tools, a disciplined investing process, and personalized instructions to foster self-direction and life-long learning among investors.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Feb 22, 2017 4:49 pm
by QualityStocks, Inc. (CIIX) Taps Traditional Chinese Medicine Market with CBD

No one should have been astonished at the discovery, reported by NPR (, of a ‘trove of cannabis plants found in (an) ancient tomb in China’. China represents a past civilization that has sprung many surprises over the centuries, and has given us some of our greatest inventions, including the compass, gunpowder, papermaking, and printing.

On par with these innovations has been Traditional Chinese Medicine (TCM), which has relied, in part, on herbal remedies (tui na). The use of plant derivatives to alleviate maladies is as natural to the Chinese as drinking tea, which itself is thought to promote dental health due to a richness of fluoride in some strains, with anti-bacterial and anti-viral properties in others, and is a good source of Vitamin A in still others. Two millennia ago, a ‘tea’ made from hemp was consumed for medical purposes. Now, Inc. (OTCQB: CIIX) is going back to those roots. The company aims to be ‘the premier provider of cannabidiol (CBD) oil to the Chinese population in mainland China’.

CBD oil is a compound extracted from the cannabis plant. However, plants bred and grown for their high tetrahydrocannabinol (THC) content are commonly referred to as marijuana. THC is psychoactive and is responsible for the ‘high’ that marijuana use provides. Other cannabis plants contain only trace amounts of THC but have high concentrations of CBD, which is the second most common cannabinoid of the 85 or so found in cannabis. Unlike THC, CBD is non-psychotropic. Plants with a preponderance of CBD are called hemp.

Hemp oil is rich in protein, polyunsaturated fatty acids, omega 6, omega 3 and insoluble fiber. It is a good source of tocopherols or Vitamin E antioxidants and is packed with minerals such as potassium, magnesium, iron, zinc, calcium, and phosphorus, as well as microelements like strontium, thorium, arsenic and chromium. Hemp oil is thought to increase immunity, counteract aging skin and improve cardiovascular health. Several studies show that the linoleic acid present in hemp oil can slow down the aging process and fight psoriasis.

There have been encouraging reports ( of CBD helping epileptics, and Citizens United for Research in Epilepsy (CURE) has called for more study ( into the use of CBD to treat epilepsy.

Unlike their western counterparts, Chinese companies have a long history of researching and developing cannabis products. Data published by the World Intellectual Property Organization (WIPO) indicate that Chinese firms account for about half of the filings for patents on cannabis products.

Late last month, CIIX announced it was launching the world’s first CBD health products online store in the Chinese language under the domain name The company will use the site to sell CBD oil products to customers in the Chinese mainland, where hemp oil-derived products are legal, and to Chinese speakers in the U.S. and Canada.

At present, the competitive landscape is clear, with virtually no rivals, and CIIX has signed an agreement with a San Diego producer to white label and distribute a number of CBD products, which, since they are not THC based, are legal in all 50 U.S. states, as well as in China.

The prospects for success are excellent. Founder and CEO of CIIX, Warren Wang, recently cited an industry study as he announced an alliance with a Chinese private equity firm to raise capital for investment in medical and recreational marijuana ventures:

“According to The CBD Report published by The Hemp Business Journal, cannabidiol is one of the fastest growing market categories in the U.S. hemp and legal marijuana industries. In 2015, the CBD industry grew from a nearly invisible market… to $202 million in consumer sales, and it is further expected to grow to $2.1 billion in consumer sales by 2020. We are very excited that CIIX is launching the world’s first CBD online store focused on providing CBD health products for Chinese-speaking customers and making it possible for them to order various types of CBD products through”

Traditional Chinese medicine is about to experience a renaissance.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Mar 01, 2017 4:43 pm
by QualityStocks, Inc. (CIIX) Set to Capitalize On Growing Cannabis Industry

Cannabis has been used for thousands of years as a form of natural remedy. But, over time, the possession of marijuana was made illegal in many countries, until now. Most recently, a new movement has taken place whereby both the medical and recreational use of cannabis has been legalized across certain states in the U.S. and a number of countries.

The marijuana industry is proving to be important in more ways than one, with Forbes stating that “A new report from New Frontier Data projects that by 2020 the legal cannabis market will create more than a quarter of a million jobs” ( The article continues to explain that this represents more than the number of jobs generated from manufacturing, government, and utilities.

Despite the changing opinions regarding the drug, China still maintains its stance that cannabis is illegal both recreationally and medically. The possession, transport, cultivation, and sale of cannabis are illegal throughout China, and penalties for cannabis-related offenses are said to be harsh. But cannabis comes in many forms, and although smoking or consuming the drug in any way is illegal, CBD oil for medical purposes has caught the eye of experts across the globe.

As the world continues to make strides toward the legalization of marijuana, demand for CBD oil continues to grow. CBD can be used in a variety of different forms, from sprays to oils and even capsules and concentrates, with expansion toward drops, soft gels, and vapes. CBD oil is being used to treat a number of conditions, including cancer, autism, ADHD, seizures, anxiety, and Crohn’s disease, among others.

According to Forbes (, The Hemp Business Journal believes “the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That’s a 700% increase from 2016.” And, despite most of the attention being on the United States after propositions for the legalization of marijuana passed in numerous states, organizations from countries across the world are tapping into this growing market.

Last month,, Inc. (OTCQB: CIIX) announced that it would be launching the first CBD health products store in Chinese. The company is aiming to become the first ever provider of CBD oil products to customers located in mainland China and to Chinese speakers in the United States and Canada. The products will be sold through CIIX’s website:

It is clear that has found a significant gap in the market, with no competition currently on the horizon serving the Chinese speaking population around the world in this way. CBD oil is one of the fastest growing market categories in the hemp and legal marijuana industries, and CIIX has positioned itself for growth thanks to its agreement with a San Diego producer that will be white labeling and distributing the company’s CBD products legally to the entirety of the United States and China.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Tue Mar 07, 2017 4:25 pm
by QualityStocks
SeeThruEquity Issues Update on (CIIX), Increases Price Target to $3.75

Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by Though in the early stages of penetrating the legal cannabis market, has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million in proceeds from stock sales of Medicine Man in 2016.

Traditionally, has delivered a broad range of products, services, and information for the Chinese speaking population, estimated at 1.2 billion people worldwide. The company provides real-time market commentary, analysis, and educational services in the Chinese language, and it offers several types of subscription-based services. Founded in 1999, the company is headquartered in Los Angeles with offices in New York City and Shanghai, China. also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

With a focus on value-added opportunities, the company has recently expanded into retail and online sales of cannabidiol (CBD) products. CBD is considered to have a broad range of potential medical applications, including the treatment of epilepsy. With multiple anecdotal claims of CDB efficacy in treating epilepsy, Great Britain-based GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD. Clinical reports show CBD is devoid of the euphoric side effects associated with THC. markets CBD products to the Chinese people through its website,

Although early in market penetration, is among the very first to capitalize on selling CBD products to 1.2 billion Chinese people. The company has previously exhibited the ability to identify and execute upon opportunity. Given its track record, it should come as no surprise if CIIX succeeds in this new venue and, subsequently, achieves SeeThruEquity’s price target.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Thu Mar 16, 2017 4:17 pm
by QualityStocks (CIIX) Helping Treat Patients with Amyotrophic Lateral Sclerosis

Late February, a study was released ( reviewing evidence that supports the use of cannabinoids to treat Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others.

Currently, ALS is treated with riluzole, a drug that controls neuronal signaling, but this drug does not cure the disease and can only slightly increase the chance of survival. With more effective therapeutic options needed to treat ALS, in-depth research has been done into the benefits of cannabinoids, the naturally occurring compounds found in the marijuana plant.

According to the article relating to the report, the cannabinoid system is involved in the pathology of ALS. A researcher shared that the data found proves that by editing CB2-mediated processes, it could change the progression of ALS and how much the endocannabinoid system could reduce excitotoxicity, neuroinflammation, and oxidative cell damage.

Testing on animals with ALS showed that cannabinoids have anti-inflammatory, antioxidant, and neuroprotective effects. It was also proven that cannabinoids can further delay the progression of the disease and prolong survival in these animals. Despite new cases of ALS being diagnosed each day, there are no obvious racial, ethnic, or socioeconomic boundaries associated with the disease.

With a shift in consumer, political, and legal views surrounding cannabis, as well as the current studies that are starting to show proof that CBD can help treat a variety of diseases, demand for CBD oil is on the rise across the globe. Companies such as (OTCQB: CIIX) are launching CBD health products in order to meet this growing demand.

Although China maintains its stance that cannabis is illegal both medically and recreationally, using CBD oil for medical purposes is allowed. As a result, is now launching the first CBD health products store in China and aims to be the first-ever provider of CBD oil products to customers in mainland China, and to Chinese speaking people in the United States and Canada.

The company aims to help people with diseases such as ALS by offering high-quality products that are both natural and legal, using compounds found in the cannabis plant that are not psychoactive. With the valid rationale to suggest the use of CBD to manage the symptoms of ALS, and the growing global need for high-quality CBD products, will be entering the market and helping treat numerous patients in two of the largest countries in the world.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Thu Mar 23, 2017 4:49 pm
by QualityStocks, Inc. (CIIX) Set to Open California Retail Store, Launches XiBiDi Biotechnology in China, Inc. (OTCQB: CIIX) is planning to open a retail store in San Gabriel, California, the same city in which the company is headquartered. The company also recently announced its new online cannabidiol (CBD) oil retail store would be operated by its newly-launched XiBiDi Biotechnology Co., Ltd subsidiary, which is headquartered in the Pudong Free-Trade Area of Shanghai, China.

XiBiDi Biotechnology will focus on the online and offline sales of health products, including a range of hemp-derived food and beverages. In a news release, Warren Wang, founder and CEO of CIIX, said he was delighted with the registration and establishment of CIIX’s new hemp company. The registration is expected to be finalized by the end of March 2017.

“XiBiDi is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 million people,” Wang said. “We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products.”

CIIX previously opened the world’s first online CBD product store in the Chinese language,, in the Industrial Building of Shanghai. It will sell CBD products, which are non-toxic and non-addictive. CBD is extracted from cannabis in the form of a natural concentrate. It is thought to have value in treating epilepsy, Alzheimer’s disease, and cirrhosis of the liver, as well as in easing the impact of the neurodegenerative disease ALS, or Lou Gehrig’s disease.

“CIIX is very excited to be the world’s first U.S. publicly traded company promoting hemp-based CBD health products and hemp foods that will help Chinese people improve their overall health,” noted Wang.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Mar 29, 2017 4:27 pm
by QualityStocks, Inc. (CIIX) Executes a First to Market Milestone

A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population. The company provides real-time market commentary, analysis, and education-related services in the Chinese language and offers several types of subscription-based services. Headquartered in Los Angeles with offices in New York City and Shanghai, the company also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

Seizing opportunity, this diverse multi-faceted company recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based therapeutic health products online store, To supply consistently high quality products, the company entered into a wholesale agreement with a well-known CBD oil health brand manufacturer in January.

Marijuana use in China is illegal, but there are no legal strictures on the sale or use of therapeutic cannabis-based oils. Cannabidiol (CBD) oil is considered to have a broad range of medical benefits and, unlike medical marijuana products, CBD oil is non-psychoactive with low THC and high CBD content. CBD has shown varying efficacy in treating epilepsy, Alzheimer’s disease and cirrhosis, as well as providing relief from anxiety and stress. CBD interacts with the body through the endocannabinoid system. The endocannabinoid system regulates the body’s homeostasis, or general state of balance, impacting such functions as mood, sleep, appetite, hormone regulation, pain and immune response. Even more benefits are expected to be uncovered upon completion of ongoing research.

Given the wide-ranging practice of holistic-based Eastern medicine, acceptance and use of CBD oils is not only a natural adjunct but also an enormous potential revenue generator for

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Apr 05, 2017 5:14 pm
by QualityStocks, Inc. (CIIX) Combating Alzheimer’s Disease through Development of CBD Health Products

China’s growing economy has proven to be beneficial to many across the country. Some of these benefits include higher living standards, better health and nutrition, and longer life expectancy. Unfortunately, China’s longer-lived population has resulted in a significant increase in the number of people having to care for seniors with various mental dysfunctions, most notably dementia and, in particular, Alzheimer’s disease.

Alzheimer’s is a neurodegenerative type of dementia that is most prominent in elderly people. The disease is a disorder that involves the death of brain cells leading to various cases of memory loss and cognitive decline. The disease starts mildly but eventually progresses to the point that patients affected often cannot recognize familiar surroundings and eventually lose almost all of their short term memory capabilities.

Recent statistics show that over 1,300 people aged 60 or over get lost or go missing every day in China ( Dementia of various forms was said to be the main cause of these disappearances. More than 70% of the elderly people who go missing have memory problems, with 25% of these having Alzheimer’s disease.

Alzheimer’s cases now makes up more than 60% of all dementia patients in China, and, because people are living longer, the number of people affected by the disease is growing rapidly., Inc. (OTCQB: CIIX), a company focused on sharing real-time market analysis to Chinese-speaking investors and which also has the aim of becoming the premier producer of cannabidiol (CBD) oil to mainland China, is hoping to help manage this growing problem.

Recent studies show that Alzheimer’s is a disease that affects the whole nervous system (, not just the brain. This means that strengthening the endocannabinoid system is extremely important to managing symptoms of Alzheimer’s, something of which CIIX is very aware. From various research, the company has found that CBD oil can be effective in restoring memory, and it plans to further study the efficacy of CBD oil for the treatment of Alzheimer’s disease.

In addition to the launch of, the world’s first online CBD health products store in Chinese, and its cannabis mobile application, will be investing in CBD drug R&D enterprises with the aim of developing a range of CBD-based drugs that can help mitigate the suffering of patients with Alzheimer’s, among other diseases.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Apr 12, 2017 6:38 pm
by QualityStocks, Inc. (CIIX) Eyes Germany’s Growing Medical Hemp Market, Inc. (OTCQB: CIIX) attended the ‘Invest 2017’ exhibition in Stuttgart, Germany, on April 7-8, 2017, anticipating that the conference would be an opportunity for CIIX to introduce its hemp companies and products to German investors, but CIIX is not alone in seeing the growth opportunities for medical cannabis in that market. CIIX operates a website for Chinese-speaking investors. It has also opened, in the Shanghai Free Trade Area, a store that distributes CBD health oil products to the global Chinese-speaking population.

Germany permits the use of medical marijuana, and it recently further loosened its regulations. Earlier this year, the country legalized medical cannabis, but it has tightly limited its prescriptions to individuals with illnesses such as chronic pain, nausea related to cancer treatments, multiple sclerosis, and epilepsy.

Germany’s Federal Institute for Drugs and Medical Devices (BfArM) has established a special marijuana agency to control the distribution of medical marijuana. The agency will oversee the cultivation and distribution of marijuana in that country. Berlin plans to have its own program by 2019 to grow cannabis at home, and the German government will solicit bids from EU countries to operate the cultivation process. Germany says it will work to ensure that only pharmaceutical grade hemp should reach patients, as noted by Lutz Stroppe, State Secretary of the Federal Ministry of Health.

CIIX sees an opportunity to participate in the German market, and it is also targeting expansion within China and throughout North America and Asia. The ‘Invest 2017’ conference was a chance to showcase the company’s hemp-based product line to the German financial community.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Fri Apr 21, 2017 4:47 pm
by QualityStocks
Epilepsy Patients are the New Focus of, Inc.’s (CIIX) CBD Health Products

In China, there are close to 10 million epilepsy patients, the Chinese Overseas Medical Advisory Service Center estimates. There is no cure in the country, although risky surgery is sometimes performed in the U.S., where there are over three million people living with epilepsy. Many patients rely on Chinese herbs for temporary control. However,’s (OTCQB: CIIX) current development plan includes making cannabidiol (CBD) products available online for people with epilepsy and Alzheimer’s disease. Its online store ( and Yelp-style mobile application are helping to serve Chinese-speaking consumers around the world, and investors as well, with a reach into the $202 million U.S. CBD industry (based on 2015 consumer sales), which is expected to exceed $2 billion by 2020.

Cannabis was used as a medicinal substance in China as early as 2700 BCE, and it was later used across India and the Middle East. Epilepsy patients were treated with cannabis as early as the 11th century. This application was studied in Europe in the 19th century, and research into the medical use of cannabis compounds took place throughout the 1930s and 1940s. Progress was hindered in 1970 as the U.S. Controlled Substances Act prohibited the production and use of any cannabis product. Today, cannabis-based products are gaining ground, and CIIX is paying close attention to the market.

A United Press International (UPI) report in December 2016 ( cited two clinical trials that found cannabidiol reduced the frequency of seizures in adults and children. In these studies, CBD was used in patients with Lennox-Gastaut syndrome and Dravet syndrome, which are rare, hard-to-treat forms of epilepsy. University of Alabama researchers found that CBD does reduce the frequency and severity of seizures, but not all patients exhibited the same benefits. Research has also indicated that CBD could interact with anti-seizure medications, causing decreases in liver function and sedation. Researchers also weren’t sure if mild to moderate side effects such as decreased appetite, sleepiness, vomiting, or diarrhea were associated with CBD.

Nonetheless, the popularity of CBD and cannabis-based products is adding fuel to the fire, and CIIX isn’t holding back either. It’s investing in enterprises focused on research and development. These include businesses studying CBD’s impact on epilepsy. Parents and caretakers have not been waiting for approval of cannabis products or traditional drugs to be approved by the U.S. Food and Drug Administration. Many have already obtained medical cannabis and seen positive results. Even the American Epilepsy Society has taken a stance, referencing anecdotal reports on the use of marijuana derivative cannabidiol in patients with treatment-resistant seizures ( It has called on both government and private funders to support research, so there’s more scientific data on the effectiveness of CBD as an epilepsy treatment.

Cannabidiol is gaining ground in the North American market. Legal in 50 states, it’s considered a food nutrient and is exported to China and over 40 other countries.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Wed Apr 26, 2017 4:41 pm
by QualityStocks, Inc. (CIIX) Raises Funds through a Private Placement, Sales of Equities, and Preferred Stock Offerings, Inc. (OTCQB: CIIX) is raising funds in a series of offerings, equity sales and a private placement to meet its liquidity needs, even as it reported a 95% gain in its year-over-year operating revenues for the three months ended February 28, 2017. It has begun a private placement of a new series of its preferred stock to its Canadian investors. In 2016, it realized $2.3 million in proceeds from its stock sales of Medicine Man Technologies, Inc. is a company which, in real-time in the Chinese language, provides analysis and educational services. It also offers consulting and advertising servies to its members. It is now focusing on the growing cannabis sector, developing online and store sales of hemp-based CBD health products. Warren Wang, chief executive officer of CIIX, said the company is in the final stages of developing websites, retail channels and marketing campaigns for the product line.

In the quarter ended February 28, 2017, it raised $5,000,043 from an offering of its Series C-2016 preferred stock. Additionally, the investors of the final $350,150 in that over-subscribed offering agreed to keep their funds on deposit with the company pending the company’s next securities placement. It was recorded on the balance sheet as an investors’ deposit. CIIX raised some $1,996,939 in cash in the nine months ended February 28, 2017, from its holdings in MDCL stock. The company still retains 41,238 shares of MDCL stock, representing $79,588 in value based on a closing market price of $1.93.

Even as its own sales performance grows, CIIX says that, since its inception, it has relied on proceeds from private placements and sales of shares of its equity securities to fund its operations. In the past two years, CIIX has realized proceeds of $2,605,000 from the issuance of its Series B-2014 stock.

For more information, visit the company’s website at

Re:, Inc. (CIIX)

PostPosted: Mon May 01, 2017 4:27 pm
by QualityStocks, Inc. (CIIX) Set to Capitalize on Meteoric Growth of CBD Market

The chemical in marijuana that causes euphoria is delta-9 tetrahydrocannabinol, or THC. There are also over 100 other cannabinoid chemicals in the plant, including cannabidiol (CBD), one of the main active chemical compounds found in marijuana. CBD doesn’t make people high, isn’t intoxicating or addictive, and is gaining widespread acceptance as a natural and effective medicinal treatment for multiple disorders. Both anecdotal evidence and pre-clinical research have pointed to CBD as having a broad range of beneficial therapeutic uses, including anti-seizure, antioxidant, neuro-protective, anti-inflammatory, analgesic, anti-tumor, anti-anxiety, and anti-psychotic properties. CBD oil has already been legalized in all 50 U.S. states and can be exported to over 40 countries, including China. With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest-growing market categories in the country. U.S.-based, Inc. (OTCQB: CIIX) is set to capitalize on this meteoric growth.

With long term focus on value-add opportunities, has consistently delivered a broad range of products, services, and information for the global Chinese speaking population since 1999. This specialized investment services company provides real-time market commentary, analysis, and education-related services in the Chinese language, and it offers several subscription-based services as well as consultation, advertising, and public relations services. After profiting from a successful investment in the marijuana market, the company recognized an immense opportunity and recently expanded into retail and online sales of CBD products. The company has a 100,000+ user base, a recognizable 18-year-old brand and a target market of nearly two billion Chinese-speaking people. is positioning to become the world’s leading Chinese medical marijuana company and to dominate this new market.

In January, the company launched the world’s first CBD health products online store in the Chinese language ( Traditional Chinese medicine embraces holistic, natural remedies, which suggests that online sales and future retail outlets could easily exceed expectations. In conjunction with these expectations, SeeThruEquity, a leading independent equity research firm, recently raised its price target for to $3.75 a share. With the stock currently trading at just over a dollar per share, could provide an exceptional opportunity to profit from the medical marijuana market and nearly two billion potential new customers.

For more information, visit the company’s website at